Cargando...
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...
Guardado en:
| Publicado en: | Int J Cancer |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Blackwell Publishing Ltd
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4312923/ https://ncbi.nlm.nih.gov/pubmed/25080865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29113 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|